share_log
  • Headlines
  • Aquestive Therapeutics Announces Completion Of Enrollment In Its Oral Allergen Challenge Study For The Development Of Its Late-Stage Pipeline Program, Anaphylm Sublingual Film

Aquestive Therapeutics Announces Completion Of Enrollment In Its Oral Allergen Challenge Study For The Development Of Its Late-Stage Pipeline Program, Anaphylm Sublingual Film

Benzinga ·  Sep 27 20:39
  • Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm (epinephrine) Sublingual Film
  • Outlines the development strategy for the Company's next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the treatment of Alopecia areata
  • Holds virtual investor day

WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today hosted a virtual investor day highlighting the Company's pipeline inclusive of Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both product candidates emerging from the Company's Adrenaverse epinephrine prodrug platform. The event included presentations by members of the Aquestive management team and by distinguished key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated